• M Schuchard, E S Krames, and R Lanning.
• Pacific Pain Treatment Centers.
• Neuromodulation. 1998 Jan 1;1(1):46-56.

AbstractObjectives. To test the efficacy and safety of intraspinal opioids for patients with nonmalignant pain. Design. A retrospective analysis on 50 patients, 37 females and 13 males, who prior to intraspinal analgesia failed all conventional therapies including strong oral opioid trials. Patients were divided into three groups according to pain type: neuropathic, nociceptive, mixed neuropathic/nociceptive. Morphine equivalent doses were noted at intervals of 1, 2, 3, 4, 5, 6, 9, 12, 24, 36, 48, 60, and 72 months. Global evaluation of pain relief (poor, fair, good, excellent) was obtained at each return visit. Dose requirements, escalations, and decreases were noted and analyzed. Side effects and complications of drug infusion or mechanical devises were noted and tabulated. Results. 7 of 7 patients with nociceptive pain had good (29%) to excellent (71%) pain relief. Sixty percent of the 16 patients with neuropathic pain had good (47%) to excellent (13%) pain relief. Seventy-two percent of the total of patients with mixed pain had good (40%) to excellent (32%) pain relief. When further subdivided, only 59% of the failed back/arachnoiditis sufferers had good (41%) to excellent (18%) pain relief while 100% of the mixed group with non-FBSS diagnoses had good (37%) to excellent (63%) pain relief. Conclusions. Long-term intrathecal opioids are efficacious, practical, and safe for the treatment of nonmalignant pain syndromes. FBSS patients respond similarly to intraspinal analgesia as the patients with neuropathic pain, while the group with mixed pain from other non-FBSS causes respond similarly to the nociceptive pain patients.1998 Blackwell Science, Inc.

16 keywords...

hide…